Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic Patent Expiration

Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic is Used for correcting hypophosphatemia in adults and pediatric patients 12 years of age and older. It was first introduced by Cmp Development Llc in its drug Potassium Phosphates on Sep 19, 2019. Another drug containing Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic is Potassium Phosphates In 0.9% Sodium Chloride. 5 different companies have introduced drugs containing Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic.


Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic Patents

Given below is the list of patents protecting Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Potassium Phosphates US10632150 Potassium phosphates composition for injection Apr 19, 2039 Cmp Dev Llc



Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List



Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic Generics

Several generic applications have been filed for Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic. The first generic version for Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic was by American Regent Inc and was approved on Oct 2, 2023. And the latest generic version is by Somerset Therapeutics Llc and was approved on Jul 11, 2024.

Given below is the list of companies who have filed for Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic generic.


1. AM REGENT

American Regent Inc has filed for 3 different strengths of generic version for Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic. All of these versions come by the name POTASSIUM PHOSPHATES. Given below are the details of the strengths of this generic introduced by Am Regent.

Strength Dosage Form Availability Application Pathway TE code Launch Date
1.18GM/5ML (236MG/ML); 1.12GM/5ML (224MG/ML) solution Prescription INTRAVENOUS AP Oct 2, 2023
3.54GM/15ML (236MG/ML); 3.36GM/15ML (224MG/ML) solution Prescription INTRAVENOUS AP Oct 2, 2023
11.8GM/50ML (236MG/ML); 11.2GM/50ML (224MG/ML) solution Prescription INTRAVENOUS AP Oct 2, 2023


2. AMNEAL

Amneal Eu Ltd has filed for 3 different strengths of generic version for Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic. All of these versions come by the name POTASSIUM PHOSPHATES. Given below are the details of the strengths of this generic introduced by Amneal.

Strength Dosage Form Availability Application Pathway TE code Launch Date
1.18GM/5ML (236MG/ML); 1.12GM/5ML (224MG/ML) solution Prescription INTRAVENOUS AP Oct 10, 2023
3.54GM/15ML (236MG/ML); 3.36GM/15ML (224MG/ML) solution Prescription INTRAVENOUS AP Oct 10, 2023
11.8GM/50ML (236MG/ML); 11.2GM/50ML (224MG/ML) solution Prescription INTRAVENOUS AP Oct 10, 2023


3. SOMERSET THERAPS LLC

Somerset Therapeutics Llc has filed for 2 different strengths of generic version for Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic. All of these versions come by the name POTASSIUM PHOSPHATES. Given below are the details of the strengths of this generic introduced by Somerset Theraps Llc.

Strength Dosage Form Availability Application Pathway TE code Launch Date
1.18GM/5ML (236MG/ML); 1.12GM/5ML (224MG/ML) solution Prescription INTRAVENOUS AP Jul 11, 2024
3.54GM/15ML (236MG/ML); 3.36GM/15ML (224MG/ML) solution Prescription INTRAVENOUS AP Jul 11, 2024